Overall, the immunosuppressive effect of TGFβ in TME seems to be of critical importance for CRC progression, and thus the therapeutic inhibition of TGFβ has been frequently regarded as a promising strategy for the treatment of CRC. The gene discussed is TGFB1; the disease is colorectal carcinoma.